STOK

Stoke Therapeutics, Inc. (STOK) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Stoke Therapeutics is a late-stage clinical biotechnology company developing RNA-based medicines using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. The company's lead product candidate, zorevunersen (STK-001), is in Phase 3 clinical trials (EMPEROR study) for Dravet syndrome. A second candidate, STK-002, is in Phase 1 trials for Autosomal Dominant Optic Atrophy (ADOA).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. YTD 2025 includes a significant non-recurring revenue recognition event.

Material Changes vs. Prior Period

• Revenue Surge: YTD revenue increased by $169.1 million compared to the prior year. This was primarily driven by the recognition of $150.8 million related to the IP License performance obligation under the new Biogen collaboration agreement signed in February 2025.
• Profitability Shift: The company reported a net income of $51.0 million for the nine months ended September 30, 2025, compared to a net loss of $78.5 million in the same period in 2024. This turnaround is attributable to the large upfront revenue recognition from Biogen.
• Operating Expenses: R&D expenses increased by $30.5 million YTD, driven by a $23.0 million increase in costs for the zorevunersen program and a $9.0 million increase in personnel-related expenses.
• Acadia Termination: On September 3, 2025, the company terminated the MECP2 and undisclosed neurodevelopmental programs under its Acadia Pharmaceuticals agreement. Rights to these targets returned to Stoke, but the company is no longer eligible for up to $662.5 million in potential milestones for those specific programs.

Guidance, Outlook, and Risks

• Liquidity: Management expects cash, cash equivalents, and marketable securities of approximately $328.6 million to fund operations through mid-2028.
• Clinical Progress:
  • Zorevunersen: The Phase 3 EMPEROR study is actively recruiting in the U.S., UK, and Japan. The company plans to meet with the FDA before year-end to discuss expedited regulatory pathways under its Breakthrough Therapy Designation.
  • STK-002: The Phase 1 OSPREY study for ADOA initiated in August 2025, with the first patient expected to be enrolled in the second half of 2025.
• Subsequent Event: Since September 30, 2025, the company sold approximately 1.8 million shares of common stock, receiving $48.7 million in net proceeds.
• Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA), enacted July 4, 2025, resulted in the reversal of previously recorded income tax expense of $1.2 million for the quarter.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure additional capital if needed, reliance on third-party manufacturers, and potential delays due to federal government shutdowns affecting FDA operations.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of revenue streams, noting that the $183M YTD revenue is heavily weighted by a one-time $150.8M license fee from Biogen, not product sales.
• Cash Burn Rate: Monitor quarterly operating cash flow to ensure the "mid-2028" runway remains valid given the increased R&D spend on zorevunersen.
• Acadia Impact: Assess the strategic and financial impact of the terminated MECP2 programs and the return of rights to Stoke.
• Biogen Collaboration: Review the terms of the Biogen agreement regarding the 70/30 cost-sharing structure for global development and the specific milestones required for future payments.
• Regulatory Timeline: Track the outcome of the upcoming FDA meeting regarding zorevunersen and the enrollment progress of the Phase 3 EMPEROR trial.